You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLansoprazole
Accession NumberDB00448  (APRD00077)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI’s available.

Structure
Thumb
Synonyms
SynonymLanguageCode
AG 1749Not AvailableNot Available
BamaliteNot AvailableNot Available
LansoprazolGerman/SpanishINN
LansoprazoleNot AvailableINN, BAN, USAN
LansoprazolumLatinINN
LanzolNot AvailableNot Available
LanzopralNot AvailableNot Available
LanzulNot AvailableNot Available
LimpidexNot AvailableNot Available
MonolitumNot AvailableNot Available
OgastroNot AvailableNot Available
OpirenNot AvailableNot Available
PrevacidNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lansoprazolecapsule, delayed release15 mgoralSTAT Rx USA LLC2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralSTAT Rx USA LLC2009-11-11Not AvailableUs
Prevacid Solutabtablet, orally disintegrating, delayed release30 mgoralRebel Distributors Corp2002-08-30Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralRebel Distributors Corp2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralRebel Distributors Corp2009-11-11Not AvailableUs
Prevacidcapsule, delayed release30 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1995-05-10Not AvailableUs
Prevacidcapsule, delayed release15 mgoralPhysicians Total Care, Inc.2000-11-28Not AvailableUs
Prevacidcapsule, delayed release30 mgoralPhysicians Total Care, Inc.2000-08-30Not AvailableUs
Prevacidtablet, orally disintegrating, delayed release30 mgoralPhysicians Total Care, Inc.2005-05-17Not AvailableUs
Prevacidtablet, orally disintegrating, delayed release15 mgoralPhysicians Total Care, Inc.2007-07-11Not AvailableUs
Prevacidtablet, orally disintegrating, delayed release30 mgoralCardinal Health2002-08-30Not AvailableUs
Prevacidcapsule, delayed release30 mgoralPd Rx Pharmaceuticals, Inc.1995-05-10Not AvailableUs
Prevacidcapsule, delayed release30 mgoralbryant ranch prepack1995-05-10Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralbryant ranch prepack2009-11-11Not AvailableUs
Prevacidcapsule, delayed release30 mgoralTakeda Pharmaceuticals America, Inc.1995-05-10Not AvailableUs
Prevacidcapsule, delayed release15 mgoralTakeda Pharmaceuticals America, Inc.1995-05-10Not AvailableUs
Prevacid Solutabtablet, orally disintegrating, delayed release15 mgoralTakeda Pharmaceuticals America, Inc.2002-08-30Not AvailableUs
Prevacid Solutabtablet, orally disintegrating, delayed release30 mgoralTakeda Pharmaceuticals America, Inc.2002-08-30Not AvailableUs
Prevacidcapsule (delayed release)15 mgoralTakeda Pharmaceuticals America IncNot AvailableNot AvailableCanada
Prevacidcapsule (delayed release)30 mgoralTakeda Pharmaceuticals America IncNot AvailableNot AvailableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lansoprazolecapsule, delayed release15 mgoralTeva Pharmaceuticals USA Inc2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralTeva Pharmaceuticals USA Inc2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release pellets15 mgoralMylan Pharmaceuticals Inc.2009-11-10Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralMylan Pharmaceuticals Inc.2009-11-10Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSandoz Inc2010-04-23Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralSandoz Inc2010-04-23Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralAidarex Pharmaceuticals LLC2010-10-15Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralRebel Distributors Corp2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralRebel Distributors Corp2010-10-15Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralAv Kare, Inc.2013-08-05Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralAv Kare, Inc.2013-08-05Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralActavis Inc2012-12-18Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralActavis Inc2012-12-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSun Pharma Global FZE2013-09-16Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralSun Pharma Global FZE2013-09-16Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralUnit Dose Services2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralMylan Institutional Inc.2009-12-01Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralBreckenridge Pharmaceutical, Inc.2012-12-18Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralBreckenridge Pharmaceutical, Inc.2012-12-18Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralREMEDYREPACK INC.2013-03-26Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralREMEDYREPACK INC.2013-07-09Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralPhysicians Total Care, Inc.2009-11-17Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPhysicians Total Care, Inc.2010-11-17Not AvailableUs
Lansoprazoletablet, orally disintegrating, delayed release30 mgoralPhysicians Total Care, Inc.2010-11-30Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralDr.Reddy's laboratories Ltd.2010-10-15Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralDr.Reddy's laboratories Ltd.2010-10-15Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWockhardt Limited2012-08-10Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralWockhardt Limited2012-08-10Not AvailableUs
Lansoprazolecapsule, delayed release pellets15 mgoralDIRECT RX2014-01-01Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSun Pharmaceutical Industries Limited2014-12-15Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralSun Pharmaceutical Industries Limited2014-12-15Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralProficient Rx LP2009-11-11Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralbryant ranch prepack2012-08-07Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWockhardt USA LLC.2012-08-10Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralWockhardt USA LLC.2012-08-10Not AvailableUs
Lansoprazolecapsule, delayed release pellets15 mgoralCadila Healthcare Limited2013-08-23Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralCadila Healthcare Limited2013-08-23Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralBlue Point Laboratoires2013-12-09Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralBlue Point Laboratoires2013-12-09Not AvailableUs
Lansoprazolecapsule, delayed release pellets15 mgoralAmerican Health Packaging2010-09-15Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralAmerican Health Packaging2010-09-15Not AvailableUs
Lansoprazolecapsule, delayed release pellets15 mgoralZydus Pharmaceuticals (USA) Inc.2013-08-23Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralZydus Pharmaceuticals (USA) Inc.2013-08-23Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPreferred Pharmaceuticals, Inc.2013-06-04Not AvailableUs
Lansoprazolecapsule, delayed release pellets30 mgoralPreferred Pharmaceuticals, Inc.2015-01-01Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralPreferred Pharmaceuticals, Inc.2010-10-15Not AvailableUs
Lansoprazolecapsule, delayed release30 mgoralPreferred Pharmaceuticals, Inc.2014-05-23Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPreferred Pharmaceuticals, Inc.2013-06-04Not AvailableUs
Lansoprazolecapsule (delayed release)15 mgoralSanis Health IncNot AvailableNot AvailableCanada
Lansoprazolecapsule (delayed release)30 mgoralSanis Health IncNot AvailableNot AvailableCanada
Lansoprazolecapsule (delayed release)30 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada
Lansoprazolecapsule (delayed release)15 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada
Lansoprazolecapsule (delayed release)30 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada
Lansoprazolecapsule (delayed release)15 mgoralPharmascience IncNot AvailableNot AvailableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prevacid 24 HRcapsule, delayed release15 mgoralNovartis Consumer Health, Inc.2009-10-12Not AvailableUs
Good Sense Lansoprazolecapsule, delayed release15 mgoralL. Perrigo Company2012-05-24Not AvailableUs
Well At Walgreens Lansoprazolecapsule, delayed release15 mgoralWalgreen Company2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWalgreen Co2012-05-18Not AvailableUs
Rugby Heartburn Treatmentcapsule, delayed release15 mgoralRugby Laboratories2014-05-05Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralRugby Laboratories Inc2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralMajor Pharmaceuticals2012-03-29Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralRite Aid Corporation2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSafeway, Inc.2012-12-31Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSafeway2014-10-07Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralThe Kroger Co.2012-09-01Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralKroger Company2012-05-18Not AvailableUs
Topcare Lansoprazolecapsule, delayed release15 mgoralTopco Associates LLC2012-09-10Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralShopko Stores Operating Co., LLC2013-06-05Not AvailableUs
Leader Lansoprazolecapsule, delayed release15 mgoralCardinal Health2012-05-30Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralH E B2012-05-18Not AvailableUs
Equaline Lansoprazolecapsule, delayed release15 mgoralSupervalu Inc2012-05-21Not AvailableUs
Shoprite Lansoprazolecapsule, delayed release15 mgoralWakefern Food Corporation2013-06-11Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralMeijer Distribution Inc2012-05-18Not AvailableUs
Careone Lansoprazolecapsule, delayed release15 mgoralAmerican Sales Company2012-05-24Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralHy Vee Inc2012-05-21Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPerrigo New York Inc2012-08-07Not AvailableUs
Good Neighbor Pharmacy Lansoprazolecapsule, delayed release15 mgoralAmerisource Bergen2012-05-31Not AvailableUs
Equate Lansoprazole Delayed Releasecapsule, delayed release15 mgoralWal Mart Stores Inc2014-05-05Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWal Mart Stores Inc2012-05-18Not AvailableUs
Sunmark Lansoprazolecapsule, delayed release15 mgoralMc Kesson2012-05-21Not AvailableUs
Smart Sense Acid Reducercapsule, delayed release15 mgoralKmart Corporation2012-05-22Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralDr. Reddy's Laboratories Limited2012-05-18Not AvailableUs
Exchange Select Lansoprazolecapsule, delayed release15 mgoralArmy & Air Force Exchange Service2012-06-11Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWestern Family Foods, Inc.2012-07-24Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWestern Family Foods Inc2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralFreds Inc2012-12-04Not AvailableUs
Healthy Accents Lansoprazolecapsule, delayed release15 mgoralDZA Brands LLC2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWockhardt Limited2012-05-18Not AvailableUs
Dg Health Lansoprazolecapsule, delayed release15 mgoralDolgencorp, LLC2012-05-21Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPublix Super Markets Inc2012-08-10Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralGericare Pharmaceuticals2013-04-25Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralP and L Development of New York Corporation2013-01-15Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralCVS Pharmacy2012-05-18Not AvailableUs
Preferred Plus Lansoprazolecapsule, delayed release15 mgoralKinray2014-06-09Not AvailableUs
Health Mart Lansoprazolecapsule, delayed release15 mgoralMc Kesson2012-05-21Not AvailableUs
Lansoprazole Heartburn Relief 24 Hourcapsule, delayed release15 mgoralQUALITY CHOICE (Chain Drug Marketing Association)2013-04-30Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralBest Choice (Valu Merchandisers Company)2012-04-30Not AvailableUs
Kirkland Signature Lansoprazole Delayed Releasecapsule, delayed release15 mgoralCostco Wholesale Company2013-12-17Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralWockhardt USA LLC.2012-05-18Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralPremier Value (Chain Drug Consortium, LLC)2012-07-06Not AvailableUs
Lansoprazolecapsule, delayed release15 mgoralSIMPLY RIGHT (Sam's West, Inc.)2013-03-30Not AvailableUs
Simply Right Lansoprazolecapsule, delayed release15 mgoralSam's West Inc2014-05-29Not AvailableUs
Heartburn Relief 24 Hourcapsule, delayed release15 mgoralOUR FAMILY (Nash Finch Company)2013-03-27Not AvailableUs
International Brands
NameCompany
AgoptonTakeda
BamaliteNot Available
LansolocCipla Medpro
LanzolCipla
LanzopralPharma Investi
LanzopranRanbaxy
LimpidexSigma-Tau
MonolitumSalvat
OgastTakeda
OgastroAbbott
OpirenAlmirall
Prevacid 24HRNovartis
Prevacid IVNovartis
ProsoganTakeda
TakepronTakeda
UlpaxHormona
ZoprolToprak
ZotonPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number103577-45-3
WeightAverage: 369.361
Monoisotopic: 369.075882012
Chemical FormulaC16H14F3N3O2S
InChI KeyMJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
IUPAC Name
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
PharmacodynamicsLansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.
Mechanism of actionLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
AbsorptionThe absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.

SubstrateEnzymesProduct
Lansoprazole
5-HydroxylansoprazoleDetails
Lansoprazole
Lansoprazole sulfoneDetails
Route of eliminationFollowing single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.
Half life1.5 (± 1.0) hours
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal pain, nausea and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lansoprazole Metabolism PathwayDrug metabolismSMP00614
Lansoprazole Action PathwayDrug actionSMP00227
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4986893 CYP2C19*3A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7007
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.547
P-glycoprotein inhibitor IInhibitor0.5357
P-glycoprotein inhibitor IINon-inhibitor0.8692
Renal organic cation transporterInhibitor0.5521
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateNon-substrate0.8659
CYP450 3A4 substrateSubstrate0.6771
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateInhibitor0.8932
CYP450 2C19 substrateInhibitor0.8993
CYP450 3A4 substrateInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8768
Ames testNon AMES toxic0.5858
CarcinogenicityNon-carcinogens0.7944
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.8734
Pharmacoeconomics
Manufacturers
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa
  • Takeda pharmaceuticals north america inc
  • Novartis consumer health inc
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Capsule (delayed release)oral15 mg
Capsule (delayed release)oral30 mg
Capsule, delayed releaseoral15 mg
Capsule, delayed releaseoral30 mg
Capsule, delayed release pelletsoral15 mg
Capsule, delayed release pelletsoral30 mg
Tablet, orally disintegrating, delayed releaseoral15 mg
Tablet, orally disintegrating, delayed releaseoral30 mg
Prices
Unit descriptionCostUnit
Prevacid SoluTab 100 15 mg Dispersible Tablet Box620.65USD box
Prevacid NapraPAC 84 15-500 mg Kit Box175.8USD box
Prevpac Miscellaneous32.02USD ea
Prevpac patient pack28.22USD each
Lansoprazole 100% powder27.54USD g
Prevacid iv 30 mg vial27.31USD vial
Prevacid dr 15 mg capsule6.25USD capsule
Prevacid SoluTab 30 mg Dispersible Tablet6.21USD dispersible tablet
Prevacid 15 mg capsule dr6.0USD capsule
Prevacid 30 mg capsule dr6.0USD capsule
Prevacid dr 30 mg capsule5.91USD capsule
Lansoprazole 15 mg Delayed Release Capsule5.9USD capsule
Lansoprazole 30 mg Delayed Release Capsule5.9USD capsule
Prevacid 15 mg solutab5.73USD tablet
Prevacid 30 mg solutab5.73USD tablet
Lansoprazole dr 15 mg capsule5.67USD capsule
Lansoprazole dr 30 mg capsule5.67USD capsule
Prevacid 30 mg Delayed Release Capsule4.45USD capsule
Prevacid 15 mg Delayed Release Capsule4.32USD capsule
Apo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Apo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Prevacid 24hr dr 15 mg capsule0.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada13270101994-02-152011-02-15
Canada24190672008-12-232021-08-17
United States46280981992-11-102009-11-10
United States73968412002-02-172022-02-17
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178-182 °CNot Available
water solubility0.97 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP2.84ALOGPS
logP3.03ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.87 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.61 m3·mol-1ChemAxon
Polarizability34.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraMS/MS1D NMR2D NMR
References
Synthesis Reference

Clarke Slemon, Bob Macel, “Preparation of omeprazole and lansoprazole.” U.S. Patent US5374730, issued December, 1986.

US5374730
General ReferenceNot Available
External Links
ATC CodesA02BC03
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AtazanavirThis gastric pH modifier decreases the levels/effects of atazanavir
BosutinibConcomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours.
CefditorenProton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
ClopidogrelLansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
EnoxacinLansoprazole may decrease the absorption of enoxacin.
IndinavirOmeprazole decreases the absorption of indinavir
ItraconazoleThe proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.
KetoconazoleThe proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
PrasugrelLansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation.
RilpivirineProton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
SucralfateSucralfate decreases the effect of lansoprazole
Food Interactions
  • Avoid alcohol.
  • Food reduces bioavailabilty, but this has very little clinical impact.
  • Take 30-60 minutes before meals.

Targets

1. Potassium-transporting ATPase alpha chain 1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Potassium-transporting ATPase alpha chain 1 P20648 Details

References:

  1. Matheson AJ, Jarvis B: Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61(12):1801-33. Pubmed
  2. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997 Sep;54(3):473-500. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 1A1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 1A1 P04798 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 1B1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 1B1 Q16678 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2C18

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C18 P33260 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 4A11

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 4A11 Q02928 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. Pubmed
  2. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. Epub 2009 Feb 24. Pubmed

2. ATP-binding cassette sub-family G member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. Epub 2008 Nov 17. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 10, 2014 19:52